PML

PML nuclear body scaffold, the group of Tripartite motif family|Ring finger proteins

Basic information

Region (hg38): 15:73994673-74047827

Links

ENSG00000140464NCBI:5371OMIM:102578HGNC:9113Uniprot:P29590AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PML gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PML gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
6
clinvar
3
clinvar
9
missense
34
clinvar
8
clinvar
7
clinvar
49
nonsense
0
start loss
0
frameshift
1
clinvar
1
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
1
clinvar
1
clinvar
2
Total 0 0 35 15 11

Variants in PML

This is a list of pathogenic ClinVar variants found in the PML region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
15-73994832-G-T not specified Uncertain significance (Feb 10, 2022)2276856
15-73994885-C-A not specified Uncertain significance (Apr 09, 2024)3308046
15-73994894-A-C Benign (Jul 06, 2018)776928
15-73994933-C-T not specified Uncertain significance (Jan 23, 2023)2464602
15-73998124-T-G not specified Uncertain significance (Dec 18, 2023)3215828
15-73998239-T-C not specified Uncertain significance (Dec 28, 2023)3215829
15-73998411-C-T PML-related disorder Likely benign (Feb 14, 2020)3051387
15-73998461-C-A not specified Uncertain significance (Feb 10, 2023)2482961
15-74022857-T-A not specified Uncertain significance (Apr 06, 2022)2385206
15-74022914-G-A not specified Uncertain significance (Mar 25, 2024)3308047
15-74023001-C-T not specified Uncertain significance (Jun 27, 2023)2606673
15-74023007-T-C not specified Uncertain significance (Mar 01, 2023)2492252
15-74023017-C-T Benign (Jul 07, 2018)774496
15-74023127-T-C not specified Uncertain significance (Apr 05, 2023)2532989
15-74023130-A-T not specified Uncertain significance (Jan 26, 2022)2272832
15-74023144-C-T Uncertain significance (Sep 25, 2019)2689792
15-74023152-C-CGAGGAGATGGCCA Uncertain significance (Dec 02, 2021)2689793
15-74023169-G-A not specified Likely benign (Oct 05, 2023)3215830
15-74023196-A-G not specified Uncertain significance (Apr 19, 2023)2538780
15-74023253-A-G not specified Uncertain significance (Apr 19, 2024)3308048
15-74023299-C-G Likely benign (May 30, 2018)744832
15-74023374-G-A PML-related disorder Likely benign (Feb 20, 2019)3052021
15-74023399-C-A not specified Uncertain significance (Dec 23, 2023)3215820
15-74024893-C-T not specified Uncertain significance (Jan 10, 2023)2474884
15-74024918-C-T Likely benign (Feb 01, 2024)3025878

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PMLprotein_codingprotein_codingENST00000268058 953140
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.2130.7871257230251257480.0000994
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.744625800.7970.00004195692
Missense in Polyphen106162.210.653471824
Synonymous1.192312550.9050.00001911839
Loss of Function4.07833.30.2400.00000181333

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001270.000120
Ashkenazi Jewish0.000.00
East Asian0.0002240.000217
Finnish0.000.00
European (Non-Finnish)0.0001080.000105
Middle Eastern0.0002240.000217
South Asian0.0001640.000163
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Isoform PML-4 has a multifaceted role in the regulation of apoptosis and growth suppression: activates RB1 and inhibits AKT1 via interactions with PP1 and PP2A phosphatases respectively, negatively affects the PI3K pathway by inhibiting MTOR and activating PTEN, and positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Isoform PML-4 also: acts as a transcriptional repressor of TBX2 during cellular senescence and the repression is dependent on a functional RBL2/E2F4 repressor complex, regulates double-strand break repair in gamma- irradiation-induced DNA damage responses via its interaction with WRN, acts as a negative regulator of telomerase by interacting with TERT, and regulates PER2 nuclear localization and circadian function. Isoform PML-6 inhibits specifically the activity of the tetrameric form of PKM. The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5) in concert with SATB1 are involved in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus. Isoform PML-2 is required for efficient IFN-gamma induced MHC II gene transcription via regulation of CIITA. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. PML also regulates transcription activity of ELF4 and can act as an important mediator for TNF-alpha- and IFN-alpha-mediated inhibition of endothelial cell network formation and migration.;
Disease
DISEASE: Note=A chromosomal aberration involving PML may be a cause of acute promyelocytic leukemia (APL). Translocation t(15;17)(q21;q21) with RARA. The PML breakpoints (type A and type B) lie on either side of an alternatively spliced exon. {ECO:0000269|PubMed:1652369, ECO:0000269|PubMed:1720570}.;
Pathway
Endocytosis - Homo sapiens (human);Influenza A - Homo sapiens (human);Acute myeloid leukemia - Homo sapiens (human);Ubiquitin mediated proteolysis - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human);Herpes simplex infection - Homo sapiens (human);TGF-Ncore;miRNA Regulation of DNA Damage Response;Wnt-beta-catenin Signaling Pathway in Leukemia;TGF-beta Signaling Pathway;DNA Damage Response;Signal Transduction;Gene expression (Transcription);Regulation of PTEN localization;Generic Transcription Pathway;Cytokine Signaling in Immune system;SUMOylation of DNA damage response and repair proteins;Post-translational protein modification;SUMO E3 ligases SUMOylate target proteins;Metabolism of proteins;RNA Polymerase II Transcription;Immune System;p73 transcription factor network;SUMOylation;regulation of transcriptional activity by pml;TGF_beta_Receptor;Validated transcriptional targets of TAp63 isoforms;PTEN Regulation;PIP3 activates AKT signaling;C-MYC pathway;Regulation of TP53 Activity through Acetylation;Regulation of TP53 Activity;Transcriptional Regulation by TP53;Interferon gamma signaling;Direct p53 effectors;Regulation of RUNX1 Expression and Activity;TNFalpha;Intracellular signaling by second messengers;Transcriptional regulation by RUNX1;mTOR signaling pathway;Interferon Signaling;TGF-beta receptor signaling (Consensus)

Recessive Scores

pRec
0.572

Intolerance Scores

loftool
0.0112
rvis_EVS
0.15
rvis_percentile_EVS
64.12

Haploinsufficiency Scores

pHI
0.136
hipred
Y
hipred_score
0.694
ghis
0.602

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.994

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Pml
Phenotype
endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; hematopoietic system phenotype; immune system phenotype;

Gene ontology

Biological process
response to hypoxia;regulation of protein phosphorylation;regulation of transcription, DNA-templated;protein import into nucleus;activation of cysteine-type endopeptidase activity involved in apoptotic process;DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest;cell cycle arrest;transforming growth factor beta receptor signaling pathway;common-partner SMAD protein phosphorylation;negative regulation of cell population proliferation;intrinsic apoptotic signaling pathway in response to DNA damage;intrinsic apoptotic signaling pathway in response to oxidative stress;response to UV;response to gamma radiation;regulation of calcium ion transport into cytosol;fibroblast migration;viral process;negative regulation of angiogenesis;protein sumoylation;myeloid cell differentiation;regulation of cell adhesion;negative regulation of cell growth;PML body organization;positive regulation of telomere maintenance;endoplasmic reticulum calcium ion homeostasis;circadian regulation of gene expression;response to cytokine;regulation of circadian rhythm;intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;entrainment of circadian clock by photoperiod;proteasome-mediated ubiquitin-dependent protein catabolic process;innate immune response;cell fate commitment;negative regulation of transcription, DNA-templated;positive regulation of fibroblast proliferation;retinoic acid receptor signaling pathway;negative regulation of interleukin-1 beta secretion;maintenance of protein location in nucleus;defense response to virus;interferon-gamma-mediated signaling pathway;branching involved in mammary gland duct morphogenesis;protein-containing complex assembly;intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress;cellular response to interleukin-4;cellular senescence;extrinsic apoptotic signaling pathway;regulation of signal transduction by p53 class mediator;negative regulation of viral release from host cell;positive regulation of nucleic acid-templated transcription;cellular response to leukemia inhibitory factor;negative regulation of ubiquitin-dependent protein catabolic process;regulation of double-strand break repair;positive regulation of extrinsic apoptotic signaling pathway
Cellular component
nuclear chromosome, telomeric region;heterochromatin;nucleus;nucleoplasm;nucleolus;cytoplasm;cytosol;nuclear matrix;PML body;early endosome membrane;extrinsic component of endoplasmic reticulum membrane
Molecular function
DNA binding;transcription coactivator activity;protein binding;zinc ion binding;SUMO transferase activity;ubiquitin protein ligase binding;SUMO binding;protein homodimerization activity;SMAD binding